UK Relonchem Ltd, receives marketing authorization for the product Levonorgestrel 1.5 mg Tablets

Marksans Pharma Limited announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA.

Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.